Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04669067
Recruitment Status : Recruiting
First Posted : December 16, 2020
Last Update Posted : September 16, 2021
Kartos Therapeutics, Inc.
Information provided by (Responsible Party):
Telios Pharma, Inc.

Brief Summary:
This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with KRT-232, a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: TL-895 Drug: KRT-232 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 58 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
Actual Study Start Date : March 31, 2021
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2024

Arm Intervention/treatment
Experimental: TL-895 combined with KRT-232

TL-895 will be administered orally, twice a day (BID) continuously starting on Day 1 in a 28-day cycle.

KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.

Drug: TL-895
TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Drug: KRT-232
KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.

Primary Outcome Measures :
  1. Primary Objective, Phase 1b: To determine the MTD/MAD and recommended Phase 2 dose (RP2D) of TL-895 in combination with KRT-232 [ Time Frame: 13 months ]
    Dose limiting toxicities will be used to established the MTD/MAD of TL-895 combined with KRT-232. The Safety Review Committee (SRC) will determine the RP2D based on safety data of the combination of TL-895 and KRT-232.

  2. Primary Objective, Phase 2: To determine the rates of complete remission (CR) and complete remission with partial hematologic recovery (CRh) [ Time Frame: 41 months ]
    The proportion of subjects who achieved CR or CRh as their best response based on the Modified 2017 European LeukemiaNet (ELN) Response Criteria (Appendix 4).

Secondary Outcome Measures :
  1. Key Secondary Objective: To characterize the peak plasma concentration (Cmax) of TL-895 and KRT-232 [ Time Frame: 13 months ]
    Cmax of TL-895 and KRT-232

  2. Key Secondary Objective: To characterize the area under the plasma concentration versus time curve (AUC) of TL-895 and KRT-232 [ Time Frame: 13 months ]
    AUC of TL-895 and KRT-232

  3. Key Secondary Objective: To characterize the time to Cmax (Tmax) of TL-895 and KRT-232 [ Time Frame: 13 months ]
    Tmax of TL-895 and KRT-232

  4. Key Secondary Objective: To determine the overall response rate (ORR) [ Time Frame: 41 months ]
    The proportion of subjects who achieve PR or better.

  5. Key Secondary Objective: To determine the duration of CR/CRh response (DOR) [ Time Frame: 41 months ]
    Median DOR (Kaplan-Meier estimate) defined as the time from first observation of CR/CRh to relapse or death from any cause, whichever occurs first. Subjects with MLFS by bone marrow biopsy performed earlier in the course of therapy who convert to CR or CRh do not require a separate bone marrow aspirate at the time of CR or CRh to document this.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • TP53 wildtype AML
  • Relapsed/Refractory to at least one prior therapy, one of which must have included a FLT-3 inhibitor
  • FLT3 mutation (FLT3-TKD or FLT3-ITD)
  • ECOG 0-2
  • Adequate hematologic, hepatic, and renal functions

Exclusion Criteria:

  • AML subtype 3
  • Prior treatment with MDM2 antagonist therapies
  • Eligible for HSCT

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04669067

Layout table for location contacts
Contact: John Mei 650-542-0136
Contact: Evelyn Hang 650-980-7779

Show Show 23 study locations
Sponsors and Collaborators
Telios Pharma, Inc.
Kartos Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Telios Pharma, Inc. Identifier: NCT04669067    
Other Study ID Numbers: TL-895-203
First Posted: December 16, 2020    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Telios Pharma, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type